Does VALSARTAN Cause Second primary malignancy? 15 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Second primary malignancy have been filed in association with VALSARTAN (valsartan). This represents 0.1% of all adverse event reports for VALSARTAN.
15
Reports of Second primary malignancy with VALSARTAN
0.1%
of all VALSARTAN reports
11
Deaths
13
Hospitalizations
How Dangerous Is Second primary malignancy From VALSARTAN?
Of the 15 reports, 11 (73.3%) resulted in death, 13 (86.7%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VALSARTAN. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does VALSARTAN Cause?
Drug ineffective (1,845)
Blood pressure increased (1,682)
Dizziness (1,527)
Headache (1,361)
Hypertension (1,341)
Acute kidney injury (1,301)
Dyspnoea (1,239)
Fatigue (1,156)
Malaise (1,139)
Hypotension (1,032)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which VALSARTAN Alternatives Have Lower Second primary malignancy Risk?
VALSARTAN vs VALTREX
VALSARTAN vs VAMOROLONE
VALSARTAN vs VANCOMYCIN
VALSARTAN vs VANDETANIB
VALSARTAN vs VARDENAFIL